EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nanosonics's Enterprise Value is A$743.7 Mil.
Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$16.0 Mil. Therefore, Nanosonics's EV-to-EBIT for today is 46.35.
The historical rank and industry rank for Nanosonics's EV-to-EBIT or its related term are showing as below:
ASX:NAN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -233.89 Med: 99.32 Max: 1292.86
Current: 46.35
During the past 13 years, the highest EV-to-EBIT of Nanosonics was 1292.86. The lowest was -233.89. And the median was 99.32.
ASX:NAN's EV-to-EBIT is ranked worse than 82.15% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 19.86
vs ASX:NAN: 46.35
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nanosonics's Enterprise Value for the quarter that ended in Dec. 2023 was A$1,224.8 Mil.
Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$16.0 Mil. Nanosonics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.31%.
Nanosonics EV-to-EBIT Historical Data
The historical data trend for Nanosonics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nanosonics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics EV-to-EBIT Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nanosonics's EV-to-EBIT falls into.
Nanosonics EV-to-EBIT Calculation
Nanosonics's EV-to-EBIT for today is calculated as:
Nanosonics's current Enterprise Value is A$743.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$16.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (ASX:NAN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nanosonics's Enterprise Value for the quarter that ended in Dec. 2023 was A$1,224.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$16.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Nanosonics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Nanosonics is a single-product firm and its trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low temperature sonically activated hydrogen peroxide mist that is suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection across patients. Nanosonics' revenue is made up of capital sales of trophon units, ongoing consumables sales, and service revenue. At June 2022, there were 29,850 trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, roughly 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in Asia-Pacific.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:NAN has been successfully added to your 